Fludarabine Phosphate

进展型多发性硬化，包括原发性进展型（PPMS）和继发性进展型（SPMS），其特征是持续的神经功能退化与脑萎缩，目前缺乏有效的疾病修饰疗法。 2025年10月15日，华中科技大学同济医学院附属同济医院王伟/田代实/秦川教授团队在Cell上发表了文章Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis，在全球首次证实自体靶向B细胞成熟抗原的嵌合抗原受体T细胞（CAR-T）疗法在治疗进展型多发性硬化中的安全性和有效性。 该研究为一项正在进行的单臂、开放标签I期探索性临床试验，所有患者在接受氟达拉滨和环磷酰胺方案的淋巴细胞清除性化疗后，回输了自体抗BCMA CAR-T细胞。通过综合性的评估手段，包括临床神经功能评分（EDSS、9HPT、T25FW等）、流式细胞术、单细胞多组学测序（scRNA-seq、scBCR/TCR-seq、CITE-seq、scATAC-seq）等，对临床安全性和疗效、CAR-T细胞的动态变化和功能特性、靶细胞清除效应及CNS免疫微环境演变进行了纵向、多维度的深度解析。 该团队长期聚焦于神经系统重大疾病的机制探索和创新治疗研究，在全球率先将靶向B淋巴细胞的CAR-T细胞疗法用于多种难治性神经免疫疾病，使83%的难治性患者实现了两年以上无复发，达到无需药物维持的长期临床缓解状态。继视神经脊髓炎（Science immunology 2024；Brain 2023；STTT 2023）、免疫介导性坏死性肌病 (PNAS 2024)、重症肌无力 (EMBO Molecular Medicine 2024) 和慢性吉兰巴雷综合征（Med 2025) 等神经免疫疾病之后，该团队在进展型多发性硬化再次取得创新性突破（Cell 2025)，进一步拓展了CAR-T细胞疗法在神经免疫病中的应用场景，同时为个体化治疗策略的开发奠定了重要基础，代表了从“免疫抑制”向“免疫重置”的治疗理念转变，有望实现神经免疫疾病长期、深度的缓解。 原文链接： https://www-cell-com.libproxy1.nus.edu.sg/cell/fulltext/S0092-8674(25)01088-8 制版人： 十一 学术合作组织 （*排名不分先后） 战略合作伙伴 （*排名不分先后） · 转载须知 【非原创文章】本文著作权归文章作者所有，欢迎个人转发分享，未经作者的允许禁止转载，作者拥有所有法定权利，违者必究。 BioArt Med Plants 人才招聘 近期直播推荐 点击主页推荐活动 关注更多最新活动！

Preliminary clinical data from the Phase 1 trial expected in 2H/2026 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 16, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. “Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now enrolling across seven autoimmune conditions,” said Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio. “In this study we are evaluating two conditioning regimens, cyclophosphamide alone and in combination with fludarabine, to explore how different conditioning regimens may impact the overall therapeutic experience. Following the recent promising safety and efficacy results of ADI-001 in lupus nephritis and systemic lupus erythematosus, we are further encouraged about the potential of ADI-001 to transform outcomes across a range of autoimmune conditions.” About the Phase 1 Trial in RA The Phase 1 study is designed to evaluate the safety, tolerability and preliminary efficacy of ADI-001 in patients with treatment-refractory RA. The study will evaluate two conditioning regimens: cyclophosphamide alone and cyclophosphamide with fludarabine. The primary objectives of the study are to evaluate the safety and tolerability of ADI-001. Secondary objectives include measuring cellular kinetics, pharmacodynamics, and disease activity scores. About Adicet’s Autoimmune Disease Phase 1 Program The Phase 1 program is evaluating ADI-001 across seven different autoimmune diseases including: lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) and RA. ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration for the potential treatment of relapsed/refractory class III or class IV LN, refractory SLE with extrarenal involvement, and SSc. The Phase 1 study in RA testing ADI-001 using two different conditioning regimens is in the context of a broader initiative at Adicet that seeks to deliver a best-in-class portfolio of therapies for autoimmune patients. This initiative includes additional ongoing preclinical programs, including gene-edited CAR T and in vivo CAR T programs targeting B cells with the potential for reducing or eliminating the need for conditioning. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Forward-Looking Statements This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: clinical development of ADI-001, including the potential safety, tolerability and efficacy of ADI-001 for the treatment of autoimmune indications, including RA; the expected progress, timing and success of the Phase 1 clinical trial of ADI-001 in RA, including site activation, continued enrollment and expectations around the timing of future data releases; ADI-001’s potential safety profile, availability as an off-the-shelf therapy and outpatient administration; and expectations regarding the Phase 1 program and ADI-001’s potential to be a best-in-class therapy for autoimmune diseases. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20251016177401/en/ Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge abowdidge@adicetbio.com Penelope Belnap Precision AQ 212-362-1200 Penelope.belnap@precisionaq.com Source: Adicet Bio, Inc.